Of the tracked stories, 3 of 3 also mention Solius Labs, the most common co-covered peer. Coverage clusters in fda-approval, which accounts for 1 of those 3, with the remainder spread across 2 other categories. UVB light therapy appears in 3 tracked Cross-Sector stories from June 18, 2026.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about UVB light therapy
Of the tracked stories, 3 of 3 also mention Solius Labs, the most common co-covered peer. Coverage clusters in fda-approval, which accounts for 1 of those 3, with the remainder spread across 2 other categories. UVB light therapy appears in 3 tracked Cross-Sector stories from June 18, 2026. The tracked stories average 2 original sources each.
Stories tracked
3
Sources per story
2
Computed from the 3 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering UVB light therapy. Shared-story counts are live from our verified record — not editorial picks.
Bainbridge Island-based startup Solius Labs announces the launch of its FDA-cleared personalized sunlight device, Solius Pro, targeting the growing consumer health and wellness market. The move positions the company at the forefront of a new category of over-the-counter light therapy without prescription.
Solius Labs launches the first OTC FDA-cleared personalized UVB light therapy device, claiming significant health benefits with minimal UV risk. For health consumers, it could offer a convenient way to boost vitamin D and improve mood without sun exposure.
The FDA has established a novel product code for Solius Pro, an over-the-counter UVB light therapy device that claims to deliver biological benefits of sunlight with dramatically reduced risk. The move signals regulatory recognition of personalized home phototherapy as a distinct category.